MeiraGTx seeks UK approval after gene therapy restores sight in children born blind [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
The AAV-AIPL1 therapy is designed to address severe sight impairment caused by mutations in the AIPL1 gene. This condition is a form of retinal dystrophy that leads to severe visual impairment from birth, with affected individuals typically only able to distinguish between light and dark. The gene therapy involves injecting functional copies of the AIPL1 gene into the retina using an adeno-associated viral (AAV) vector, aiming to restore retinal cell function and prevent degeneration. Results from four of the 11 children were published in The Lancet on 21 February. The first four children treated were aged one to three years with severe retinal dystrophy linked to mutations in the AIPL1 gene. Each child received the therapy in one eye through subretinal injection. Outcome measures included visual acuity assessments, functional vision evaluations, visual evoked potentials, and retinal structure imaging. Before treatment, the children's visual acuity was limited to light percepti
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx (NASDAQ:MGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- MeiraGTx (NASDAQ:MGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx ConferencePR Newswire
- MeiraGTx (NASDAQ:MGTX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- MeiraGTx Reports Third Quarter 2025 Financial and Operational ResultsGlobeNewswire
MGTX
Earnings
- 11/13/25 - Miss
MGTX
Sec Filings
- 12/23/25 - Form 4
- 11/24/25 - Form 4
- 11/13/25 - Form SCHEDULE
- MGTX's page on the SEC website